OBJECTIVE: Preclinical investigations have established that methamphetamine (MA) produces long-term changes in dopamine (DA) neurons in the striatum. Human studies have suggested similar effects and correlated motor and cognitive deficits. The present study was designed to further our understanding of changes in brain function in humans that might result from chronic high dose use of MA after at least 3 months of abstinence. METHOD: Brain function in abstinent users was compared to controls using neuroimaging of monoamine transporters and cognitive assessment. Striatal levels of DA transporter (DAT) and vesicular monoamine transporter type-2 (VMAT2) were determined using [11C]methylphenidate and [11C]dihydrotetrabenazine positron emission tomography, respectively. Cognitive function was evaluated using tests of motor function, memory, learning, attention, and executive function. RESULTS: Striatal DAT was approximately 15% lower and VMAT2 was 10% lower in MA abusers across striatal subregions. The MA abusers performed within the normal range but performed more poorly compared to controls on three of the 12 tasks. CONCLUSIONS: Failure to find more substantial changes in transporter levels and neurocognitive function may be attributed to the length of time that MA users were abstinent (ranging from 3 months to more than 10 years, mean 3 years), although there were no correlations with length of abstinence. Persistent VMAT2 reductions support the animal literature indicating a toxic effect of MA on nigrostriatal nerve terminals. However, the magnitude of the MA effects on nigrostriatal projection integrity is sufficiently small that it is questionable whether clinical signs of DA deficiency are likely to develop.
OBJECTIVE: Preclinical investigations have established that methamphetamine (MA) produces long-term changes in dopamine (DA) neurons in the striatum. Human studies have suggested similar effects and correlated motor and cognitive deficits. The present study was designed to further our understanding of changes in brain function in humans that might result from chronic high dose use of MA after at least 3 months of abstinence. METHOD: Brain function in abstinent users was compared to controls using neuroimaging of monoamine transporters and cognitive assessment. Striatal levels of DA transporter (DAT) and vesicular monoamine transporter type-2 (VMAT2) were determined using [11C]methylphenidate and [11C]dihydrotetrabenazine positron emission tomography, respectively. Cognitive function was evaluated using tests of motor function, memory, learning, attention, and executive function. RESULTS: Striatal DAT was approximately 15% lower and VMAT2 was 10% lower in MA abusers across striatal subregions. The MA abusers performed within the normal range but performed more poorly compared to controls on three of the 12 tasks. CONCLUSIONS: Failure to find more substantial changes in transporter levels and neurocognitive function may be attributed to the length of time that MA users were abstinent (ranging from 3 months to more than 10 years, mean 3 years), although there were no correlations with length of abstinence. Persistent VMAT2 reductions support the animal literature indicating a toxic effect of MA on nigrostriatal nerve terminals. However, the magnitude of the MA effects on nigrostriatal projection integrity is sufficiently small that it is questionable whether clinical signs of DA deficiency are likely to develop.
Authors: T W Robbins; M James; A M Owen; B J Sahakian; A D Lawrence; L McInnes; P M Rabbitt Journal: J Int Neuropsychol Soc Date: 1998-09 Impact factor: 2.892
Authors: N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan Journal: J Neurosci Date: 2001-12-01 Impact factor: 6.167
Authors: Thomas E Nordahl; Ruth Salo; Kate Possin; David R Gibson; Neil Flynn; Martin Leamon; Gantt P Galloway; Adolf Pfefferbaum; Daniel M Spielman; Elfar Adalsteinsson; Edith V Sullivan Journal: Psychiatry Res Date: 2002-11-30 Impact factor: 3.222
Authors: Y Sekine; M Iyo; Y Ouchi; T Matsunaga; H Tsukada; H Okada; E Yoshikawa; M Futatsubashi; N Takei; N Mori Journal: Am J Psychiatry Date: 2001-08 Impact factor: 18.112
Authors: T J Ornstein; J L Iddon; A M Baldacchino; B J Sahakian; M London; B J Everitt; T W Robbins Journal: Neuropsychopharmacology Date: 2000-08 Impact factor: 7.853
Authors: Warren K Bickel; David P Jarmolowicz; E Terry Mueller; Kirstin M Gatchalian; Samuel M McClure Journal: Psychopharmacology (Berl) Date: 2012-03-24 Impact factor: 4.530
Authors: Kimber L Price; Stacia M DeSantis; Annie N Simpson; Bryan K Tolliver; Aimee L McRae-Clark; Michael E Saladin; Nathaniel L Baker; Mark T Wagner; Kathleen T Brady Journal: Am J Addict Date: 2011-07-18
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: David M Hedges; J Daniel Obray; Jordan T Yorgason; Eun Young Jang; Vajira K Weerasekara; Joachim D Uys; Frederick P Bellinger; Scott C Steffensen Journal: Neuropsychopharmacology Date: 2017-11-29 Impact factor: 7.853
Authors: I Boileau; D Payer; B Chugani; D S S Lobo; S Houle; A A Wilson; J Warsh; S J Kish; M Zack Journal: Mol Psychiatry Date: 2013-12-10 Impact factor: 15.992
Authors: Jordan E Cattie; Steven Paul Woods; Jennifer E Iudicello; Carolina Posada; Igor Grant Journal: J Neuropsychiatry Clin Neurosci Date: 2012 Impact factor: 2.198
Authors: Thomas F Newton; Malcolm S Reid; Richard De La Garza; James J Mahoney; Antonio Abad; Rany Condos; Joseph Palamar; Perry N Halkitis; Jurji Mojisak; Ann Anderson; Shou-Hua Li; Ahmed Elkashef Journal: Int J Neuropsychopharmacol Date: 2008-07-29 Impact factor: 5.176